Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: porphyria + porphyria: + 1,240,000  Related to the article below (Last Update: 8/5/2008)


Calgary Herald
Duller than fiction: Memoir too meandering
Calgary Herald,  Canada - Jul 27, 2008
... named for Allende's daughter, who died at 28 in 1993 of a rare blood disorder known as porphyria (think The Madness of King George). ...
Clinuvel gets orphan-drug status in US
The Age, Australia - Jul 28, 2008
Erythropoietic porphyrias is a rare genetic disease found in people with fair skin. It is characterised by severe light-sensitivity of the skin, ...ASX:CUV
Portrait of a lady
guardian.co.uk, UK - Jul 18, 2008
... Porphyria's homicidally possessive lover; and an exasperated Andrea del Sarto, who feels that his other half, the high-maintenance Lucrezia, ...
James Greisler '10 Studying Medical Applications of Carbohydrates
Hamilton College News, NY - Jul 21, 2008
Current anti-cancer drugs use porphyrins, molecules that absorb directed laser light and use it to kill tumor cells. Although porphyrin's ability to kill ...

Best Syndication
Treating Acne - Laser Acne Treatment 101
Best Syndication, CA - Jul 21, 2008
These Porphyrins generate singlet oxygen 102 when targeted by the light pulses; this kills the p. acnes bacteria causing the infection. ...
Clinuvel's CUV1647 granted orphan drug designation by US FDA
Australian Life Scientist, Australia - Jul 28, 2008
Afamelanotide is a photoreceptive drug designed for use in the management of erythopoietic porphyrias, a rare group of metabolic disorders which cause ...ASX:CUV
England v South Africa - As It Happened
Buzzle, CA - Jul 14, 2008
Ian also adds: "Red wine also works, but then you have to admit to porphyria." 141st over: South Africa 346-2 (Amla 72 Kallis 10)"Sorry to drag this back to ...
FDA grants orphan-drug status for skin-disease treatment
SmartBrief, DC - Jul 29, 2008
The FDA granted orphan-drug designation to Clinuvel Pharmaceuticals' afamelanotide as a treatment for erythropoietic porphyrias, a rare genetic disorder ...
FDA grants orphan-drug status for skin-disease treatment
SmartBrief, DC - Jul 29, 2008
The FDA granted orphan-drug designation to Clinuvel Pharmaceuticals' afamelanotide as a treatment for erythropoietic porphyrias, a rare genetic disorder ...
Source: Google News

Development of chronic hepatic porphyria (porphyria cutanea tarda) with inherited uroporphyrinogen … -
M Doss, H Sauer, R von Tiepermann, AM Colombi - Int J Biochem, 1984 - ncbi.nlm.nih.gov
Development of chronic hepatic porphyria (porphyria cutanea tarda) with inherited
uroporphyrinogen decarboxylase deficiency under exposure to dioxin. ...

THE PORPHYRIAS -
G DEAN - British Medical Bulletin, 1969 - British Council
... 1 Porphyria variegata 2 Intermittent acute porphyria (pyrroloporphyria) 3
Coproporphyria 4 Erythropoictic porphyrias 5 Symptomatic porphyria 6 The syndrome ...

Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. -
S Fargion, A Piperno, MD Cappellini, M Sampietro, … - Hepatology, 1992 - ncbi.nlm.nih.gov
1992 Dec;16(6):1322-6. Comment in: Hepatology. 1995 Jun;21(6):1754-5. Hepatitis
C virus and porphyria cutanea tarda: evidence of a strong association. ...

Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. -
AG Roberts, SD Whatley, RR Morgan, M Worwood, GH … - Lancet, 1997 - ncbi.nlm.nih.gov
... 1997 Apr 5;349(9057):1025-6. Increased frequency of the haemochromatosis
Cys282Tyr mutation in sporadic porphyria cutanea tarda. ...

An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase … -
JP Kushner, AJ Barbuto, GR Lee - Journal of Clinical Investigation, 1976 - pubmedcentral.nih.gov
... Copyright notice. An inherited enzymatic defect in porphyria cutanea tarda:
decreased uroporphyrinogen decarboxylase activity. JP ...

Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated … -
R Kauppinen, P Mustajoki - Medicine (Baltimore), 1992 - ncbi.nlm.nih.gov
Medicine (Baltimore). 1992 Jan;71(1):1-13. Prognosis of acute porphyria: occurrence
of acute attacks, precipitating factors, and associated diseases. ...

Porphyria cutanea tarda. -
GH Elder - Semin Liver Dis, 1998 - ncbi.nlm.nih.gov
Porphyria cutanea tarda. ... Porphyria cutanea tarda (PCT) is a skin disease that results
from decreased activity of uroporphyrinogen decarboxylase (UROD). ...

Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. -
M DeCastro, J Sanchez, JF Herrera, A Chaves, R … - Hepatology, 1993 - ncbi.nlm.nih.gov
1993 Apr;17(4):551-7. Comment in: Hepatology. 1995 Jun;21(6):1754-5. Hepatitis C
virus antibodies and liver disease in patients with porphyria cutanea tarda. ...

… results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria -
PN Meissner, TA Dailey, RJ Hift, M Ziman, AV … - Nature Genetics, 1996 - palgrave-journals.com
... A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme
activity and is prevalent in South Africans with variegate porphyria. ...

High prevalence of the His 63 Asp HFE mutation in italian patients with porphyria cutanea tarda -
M Sampietro, A Piperno, L Lupica, C Arosio, A … - Hepatology, 1998 - doi.wiley.com
... With Porphyria Cutanea Tarda ... Sporadic porphyria cutanea tarda (PCT) is caused by
a reduced activity of uroporphyrinogen decarboxylase (URO-D) in the liver. ...

Source: Google Scholar
 

Porphyria

Porphyria is a group of different disorders caused by abnormalities in the chemical steps leading to the production of heme, a substance that is important in the body. The largest amounts of heme are in the blood and bone marrow, where it carries oxygen. Heme is also found in the liver and other tissues.

Multiple enzymes are needed for the body to produce heme. If any one of the enzymes is abnormal, the process cannot continue and the intermediate products, porphyrin or its precursors, may build up and be excreted in the urine and stool.

The porphyria disorders can be grouped by symptoms—whether they affect the skin or the nervous system. The cutaneous porphyrias affect the skin. People with cutaneous porphyria develop blisters, itching, and swelling of their skin when it is exposed to sunlight. The acute porphyrias affect the nervous system. Symptoms of acute porphyria include pain in the chest, abdomen, limbs, or back; muscle numbness, tingling, paralysis, or cramping; vomiting; constipation; and personality changes or mental disorders. These symptoms appear intermittently.

Article continues below and (thank you)

 

The porphyrias are inherited conditions, and the genes for all enzymes in the heme pathway have been identified. Some forms of porphyria result from inheriting an abnormal gene from one parent (autosomal dominant). Other forms are from inheriting an abnormal gene from each parent (autosomal recessive). The risk that individuals in an affected family will have the disease or transmit it to their children is quite different depending on the type.

Attacks of porphyria can develop over hours or days and last for days or weeks. Porphyria can be triggered by drugs (barbiturates, tranquilizers, birth control pills, sedatives), chemicals, fasting, smoking, drinking alcohol, infections, emotional and physical stress, menstrual hormones, and exposure to the sun.

Porphyria is diagnosed through blood, urine, and stool tests. Diagnosis may be difficult because the range of symptoms is common to many disorders and interpretation of the tests may be complex. Each form of porphyria is treated differently. Treatment may involve treating with heme, giving medicines to relieve the symptoms, or drawing blood. People who have severe attacks may need to be hospitalized.

 

For More Information

American Porphyria Foundation
P.O. Box 22712
Houston, TX 77227
Phone: 713–266–9617
Email: porphyrus@aol.com
Internet: www.porphyriafoundation.com

National Organization for Rare Disorders Inc. (NORD)
55 Kenosia Avenue
P.O. Box 1968
Danbury, CT 06813–1968
Phone: 1–800–999–6673 or 203–744–0100
Fax: 203–798–2291
Email: orphan@rarediseases.org
Internet: www.rarediseases.org

American Liver Foundation (ALF)
75 Maiden Lane, Suite 603
New York, NY 10038–4810
Phone: 1–800–GO–LIVER (465–4837),
1–888–4HEP–USA (443–7872),
or 212–668–1000
Fax: 212–483–8179
Email: info@liverfoundation.org
Internet: www.liverfoundation.org

 

Additional Information on Porphyria

The National Digestive Diseases Information Clearinghouse collects resource information on digestive diseases for National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Reference Collection. This database provides titles, abstracts, and availability information for health information and health education resources. The NIDDK Reference Collection is a service of the National Institutes of Health.

To provide you with the most up-to-date resources, information specialists at the clearinghouse created an automatic search of the NIDDK Reference Collection. To obtain this information, you may view the results of the automatic search on Porphyria.

If you wish to perform your own search of the database, you may access and search the NIDDK Reference Collection database online.



National Digestive Diseases Information Clearinghouse

2 Information Way
Bethesda, MD 20892–3570
Email: nddic@info.niddk.nih.gov

The National Digestive Diseases Information Clearinghouse (NDDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health of the U.S. Department of Health and Human Services. Established in 1980, the Clearinghouse provides information about digestive diseases to people with digestive disorders and to their families, health care professionals, and the public. The NDDIC answers inquiries, develops and distributes publications, and works closely with professional and patient organizations and Government agencies to coordinate resources about digestive diseases.

Publications produced by the Clearinghouse are carefully reviewed by both NIDDK scientists and outside experts.

This publication is not copyrighted. The Clearinghouse encourages users of this publication to duplicate and distribute as many copies as desired.


NIH Publication No. 03–4632
March 2003

 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast